Table 3.
Adherence to treatment guidelines and blood pressure control in previous studies compared with the present study
| Country | Year | Study population | Population sampling | Number of patients | Guideline lipid-lowering therapy prescription,a % | Guideline antihypertensive prescription,a % | Controlled blood pressure |
|---|---|---|---|---|---|---|---|
| Belgium10 | 2010 | High riskb | Selected sample from multiple centres | 11 069 | 80 | 68 | 13 |
| Italy11 | 2006 | High riskb | Random sample from multiple centres | 3120 | 56 | 70 | 28 |
| Italy12 | 2010 | High riskb | Random sample from multiple centres | 5731 | – | 67 | – |
| Switzerland13 | 2010 | High riskb | Entire population from study area | 23 892 | 71 | 77 | 62 |
| cEurope14 | 2010 | Primary prevention | Patients attending study clinic | 4366 | 50 | 86 | 29 |
| Canada15 | 2012 | High riskb | Entire population from study area | 4931 | – | 94 | 50 |
| UK: present study | 2014 | Primary prevention | Entire population from study area | 12 349 | 80 | 88 | 56 |
| UK: present study | 2014 | Secondary prevention | Entire population from study area | 2550 | 74 | 91 | 62 |
a
Medication prescriptions in those eligible for treatment (according to relevant guidelines).
b
Existing cardiovascular disease or high risk because of existence of diabetes, chronic kidney disease or >20% cardiovascular risk score.
c
Belgium (n = 106), Bulgaria (n = 327), Croatia (n = 398), Finland (n = 518), Germany (n = 206), Italy (n = 548), Latvia (n = 321), Poland (n = 394), Romania (n = 485), Slovenia (n = 163), Spain (n = 519), UK (n = 381).